General Infectious Disease News Articles

Infectious Dis.

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bertino JS et al. – The low minimum inhibitory concentrations and high attainment of pharmacodynamic targets with besifloxacin may contribute to a lower risk for the emergence of bacterial resistance, although further studies are needed. These data indicate that besifloxacin ophthalmic suspension 0.6% is an important new option for the treatment of bacterial conjunctivitis.

Exclusive Author Commentary
Joseph S Bertino, 09/24/09

This article discusses a new opthalmic antibiotic besifloxacin and its use in bacterial conjunctivitis. Antibiotic resistance continues to be a major problem in treatment. Newer agents such as besifloxacin may be useful in drug resistant bacterial infections. Besifloxacin optimized the pharmacodynamic ratios needed to attain good bacterial cure, and to potentially prevent the development of resistance. In clinical trials, besifloxacin was used for a 5 day treatment, however, the FDA requested a 7 day treatment in the label, no reason given.

Today in Ophthalmic Infections...keeping you current

Contact Lens-Related Acanthamoeba Keratitis
Optometry and Vision Science, 12/11/09

Leishmaniasis of the eyelid mimicking an infundibular cyst and review of the literature on ocular leishmaniasis
International Journal of Infectious Diseases, 12/10/09

Preoperative topical moxifloxacin 0.5% and povidone–iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac
Journal of Cataract & Refractive Surgery, 12/09/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address